Pipeline

Pipeline

PRE-CLINICAL
Undisclosed targets
Neuroscience
Undisclosed targets
Cannabinoids
CombiPlex
Exploratory activities
Undisclosed target
Ras/Raf/MAP kinase pathway1
JZP898 (WTX-613)2
Conditionally-activated IFNα
Undisclosed targets
Oncology
PHASE 1
JZP3243
Oxybate extended-release formulation
JZP441 (DSP-0187)2
Orexin-2 receptor agonist
Additional Cannabinoids
Neuropsychiatry targets
JZP815
Pan-Raf Inhibitor Program
Raf & Ras mutant
Zanidatamab2
HER2-targeted bispecific antibody
Breast cancer
JZP341
(Long-acting Erwinia asparaginase)
Solid tumors
JZP351 (Vyxeos)
Low Intensity Dosing for higher risk MDS4
PHASE 2
Suvecaltamide (JZP385)
Essential tremor
Suvecaltamide (JZP385)
Parkinson’s Disease Tremor
JZP1505
PTSD
Zanidatamab2
HER2-targeted bispecific antibody
  • 2L zani monotherapy for BTC6 (Pivotal trial)
  • Additional trials ongoing in BTC, GEA and CRC
  • Multiple trials ongoing in breast cancer
JZP351
  • HR-MDS (EMSCO)7
  • Newly diagnosed older adults with HR-AML7
JZP351 + other approved therapies
  • R/R AML or HMA Failure MDS4
  • de novo or R/R AML4
PHASE 3
Cannabidiol (Epidyolex)
LGS, DS, TSC in Japan

Zanidatamab2
HER2-targeted bispecific antibody
1L zani + chemo ± tislelizumab for GEA8
(Pivotal trial)

Lurbinectedin (Zepzelca)1
1L treatment SCLC in combination with Tecentriq® (atezolizumab)
JZP351
  • AML or HR-MDS >60 yrs (AML18)7
  • Newly diagnosed adults with standard- and HR-AML (AMLSG)7
  • Newly diagnosed <22 yrs with AML (COG)7

Neuroscience
Oncology

1. Partnered collaboration; 2. Acquired; 3. Planned; 4. Jazz & MD Anderson Cancer Center collaboration study; 5. JZP150 is a fatty acid amide hydrolase inhibitor which modulates the endocannabinoid anandamide; 6. HERIZON-BTC-01; 7. Cooperative group study; 8. HERIZON-GEA-01. 1L = first line, 2L = second line, AML = acute myeloid leukemia, COG = Children’s Oncology Group, BTC = biliary tract cancers, CRC = colorectal cancer, DS = Dravet syndrome, EMSCO = European Myelodysplastic Neoplasms Cooperative Group, GEA = gastroesophageal adenocarcinoma, HMA = hypomethylating agents, HR = high-risk, HRD+ = homologous recombinant deficient positive, LGS = Lennox-Gastaut syndrome, MDS = myelodysplastic syndromes, PTSD = post-traumatic stress disorder, R/R = relapsing/refractory, SCLC = small cell lung cancer, SG = study group, TSC = Tuberous sclerosis complex.